Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is seeing a little pop after news.
As of 11.52, ADMP stock gained by 5.16% at $0.75. More than 1.70 million shares have been traded hands. ADMP opened at .002 and has traded between .0021 and .0026.
ADMP Issues News
Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
- ADMP announced that the New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration (FDA) for ZIMHI™, a naloxone injection product candidate intended for the treatment of opioid overdose.
“Based on FDA feedback received during our Type A meeting in April, we have resubmitted our NDA for ZIMHI, which I am confident fully addresses the issues raised in the November 13, 2020 Complete Response Letter,” said Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals.
“We are committed to working collaboratively with the agency as it conducts its review of the resubmitted NDA. I continue to believe the availability of additional naloxone products, especially our higher dose intramuscular injection product, which has definite advantages over the two approved intranasal products, could potentially save thousands of lives.”
|SHARES OUTSTANDING||148.89 M|
|SHARE FLOAT (%)||147.32 M (98.95%)|
|% HELD BY INSTITUTIONS||10.67|
Recent Stock Performance
|+/- EMA(20)||0.77 (-2.60%)|
|+/- SMA(50)||0.87 (-13.79%)|
|+/- SMA(200)||0.86 (-12.79%)|
|CCI20||-81.7150||Sell||Chaikin Money Flow||0.0389||Neutral|
|MACD||-0.0680||Sell||Money Flow Index||57.8446||Sell|
|STOCH (14,3)||12.0244||OverSold||STOCH RSI||0.8249||OverBought|